Výsledky vyhledávání

P108 Development and evaluation of the i-Tracker Risankizumab and i-Tracker Anti-Risankizumab kits: rapid and innovative tests intended for monitoring patients treated with Risankizumab

Autor: G Khater, G Noguier, S Daviere, C Montaillier, V Guilbert

Publikováno v: Journal of Crohn's and Colitis. 17:i272-i273

Background Risankizumab is a human monoclonal antibody directed against the cytokine IL-23. This drug is commonly used for the treatment of patients with chronic inflammatory diseases such as psoriasis. Risankizumab is about to get an indication in C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec8b9e020b051f9f7f8b8e2358140a8a
https://doi.org/10.1093/ecco-jcc/jjac190.0238

Zobrazit plný text záznamu

P057 Development and evaluation of the i-Tracker Certolizumab and i-Tracker Anti-Certolizumab kits: rapid and innovative tests intended for monitoring patients treated with Certolizumab

Autor: G Khater, G Noguier, S Daviere, V Guilbert, C Montaillier

Publikováno v: Journal of Crohn's and Colitis. 17:i224-i224

Background Certolizumab is a human monoclonal antibody directed against TNFα. This drug is commonly used for the treatment of patients with inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis or even psoriatic arthritis. Curre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32a3d566e5bab267661b28f80f2a6dfc
https://doi.org/10.1093/ecco-jcc/jjac190.0187

Zobrazit plný text záznamu

P092 Development and evaluation of i-Tracker Ustekinumab and i-Tracker Anti-ustekinumab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with ustekinumab

Autor: G Noguier, L Colombeau, S Daviere, E Parussini, C Montaillier, Y Yang

Publikováno v: Journal of Crohn's and Colitis. 15:S191-S191

Background Ustekinumab, a monoclonal antibody directed against IL12/23, is a drug widely used for the treatment of Chronic Inflammatory Diseases (Psoriasis, Crohn’s disease, etc.). Therapeutic Drug Monitoring is currently proposed to provide useful

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f65199905166dccb48f41578f9de4601
https://doi.org/10.1093/ecco-jcc/jjab076.221

Zobrazit plný text záznamu

P693 Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab

Autor: G Noguier, L Colombeau, S Daviere, E Parussini, C Montaillier

Publikováno v: Journal of Crohn's and Colitis. 14:S563-S563

Background Infliximab, a monoclonal antibody directed against TNFα, is a drug widely used for the treatment of inflammatory diseases (rheumatoid arthritis, Crohn’s disease, etc.). Therapeutic drug monitoring is currently proposed to provide useful

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c7388740a512345f3494cc775b0d86d
https://doi.org/10.1093/ecco-jcc/jjz203.821

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání